Clinical utility of large language models in metastatic prostate cancer: A multicenter expert validation for decision support
European Journal of Cancer · 2026-05 · 238 · 116667
DOI: 10.1016/j.ejca.2026.116667 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift European Journal of Cancer, 2026-05. Verfasst von Yinsong Chen und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Large Language Models, Decision Support Systems, Clinical. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 40 Literaturangaben. Gefördert von: Huazhong University of Science and Technology.
Abstract (Originalsprache)
BACKGROUND: Initial systemic treatment planning for metastatic prostate cancer (mPCa) requires rapid synthesis of heterogeneous clinical and biomarker information. Large language models (LLMs) could assist clinicians, but their safety and acceptability in this high-stakes setting remain uncertain. METHODS: We conducted a multicenter retrospective evaluation of 238 consecutive mPCa cases from three tertiary centers (2018-2025). Five contemporary LLMs were tested via publicly available web interfaces under a locked, zero-shot prompting protocol to generate a clinical summary, a first-line systemic treatment recommendation, and a rationale. Outputs underwent two-stage assessment: (1) multidisciplinary team (MDT) binary safety adjudication using a one-strike gate with a prespecified taxonomy of critical errors; unsafe outputs were assigned a Likert score of 1 for all domains; (2) three senior medical oncologists independently rated safety-passed outputs on 5-point Likert scales for summary accuracy, guideline-concordant and patient-tailored recommendations, and rationale quality. Paired ordinal outcomes were analyzed with Friedman tests and Holm-adjusted post hoc comparisons, and binary safety outcomes with Cochran's Q and McNemar tests. RESULTS: Safety rates ranged from 79.0% to 84.9%. Among safety-passed outputs, mean utility scores (5-point Likert) were in the low-to-mid 4 range. Between-model differences were most apparent for summarization, whereas treatment recommendations and rationales showed modest separation after multiplicity adjustment. Failures clustered in hard cases with incomplete documentation and were dominated by missingness-related extraction errors, disease-state/pathway errors, guideline logic deviations, and safety-check omissions. CONCLUSIONS: Current LLMs can support mPCa care as drafting assistants, but ∼15%-21% of outputs breached safety thresholds under a strict gate, precluding unsupervised use at initial treatment-planning encounters.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Radiology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
- Department of Urologic Oncology, First Affiliated Hospital, School of Medicine, Shihezi University, Shihezi, Xinjiang, China.
- Department of Oncology, The Friendship Hospital of Ili Kazak Autonomous Prefecture, Ili Kazak Autonomous Prefecture, Xinjiang, China.
- Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
- Department of Radiology, Xiangyang Central Hospital, Affiliated Hospital of Hubei University of Arts and Science, Xiangyang, Hubei, China.
- Department of Radiology, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Third Hospital of Shanxi Medical University, Tongji Shanxi Hospital, Taiyuan, Shanxi, China.
Förderung
- Huazhong University of Science and Technology
Zitieren
APA
Chen, Y., He, K., Qu, W., Ma, L., Su, X., Liu, X., Kang, Z., Li, F., Yan, J., Wang, Z., Li, J., & Li, Z. (2026). Clinical utility of large language models in metastatic prostate cancer: A multicenter expert validation for decision support. European Journal of Cancer, 238, 116667. https://doi.org/10.1016/j.ejca.2026.116667
Vancouver
Chen Y, He K, Qu W, Ma L, Su X, Liu X, et al. Clinical utility of large language models in metastatic prostate cancer: A multicenter expert validation for decision support. European Journal of Cancer. 2026;238:116667. doi:10.1016/j.ejca.2026.116667
BibTeX
@article{Chen2026,
author = {Chen, Yinsong and He, Kangwen and Qu, Weinuo and Ma, Luping and Su, Xing and Liu, Xinqi and Kang, Zhen and Li, Feng and Yan, Junrong and Wang, Zhibo and Li, Jing and Li, Zhen},
title = {Clinical utility of large language models in metastatic prostate cancer: A multicenter expert validation for decision support},
journal = {European Journal of Cancer},
year = {2026},
volume = {238},
pages = {116667},
doi = {10.1016/j.ejca.2026.116667}
}
EUVIMED